Associated Genetic Biomarkers
CLEC12A status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CLEC12A status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with CLEC12A status in the inclusion eligibility criteria most commonly target acute myeloid leukemia .
The most frequent alteration to serve as an inclusion eligibility criterion is CLEC12A Expression .
Cll-1 car t cells, cyclophosphamide, and fludarabine are the most frequent therapies in trials with CLEC12A as an inclusion criteria .
Significance of CLEC12A in Diseases
Acute Myeloid Leukemia +
CLEC12A is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CLEC12A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.